AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05673902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPH-104
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
Study NCT04003142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: Oral tablet
Study NCT04003142 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral Tablet
Study NCT00950209 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: infusion of Endolipide and heparin
Description: an infusion with Endolipide 20 % (12,5 ml/h) and heparin (250 U/h) to prevent the suppressive effect of insulin on plasma free fatty acids
Study NCT00950209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hyperglycaemic hyperinsulinic clamp
Description: a hyperglycaemic hyperinsulinic clamp to maintain plasma glucose around 2 g/l to prevent the decreasing effect of insulin on plasma glucose.
Study NCT01387646 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Project IMAGE
Description: Participants in the intervention arm will be interviewed at baseline, given a targeted physical exam including a STI/HIV screen, pap smear and contraception counseling and enrolled in the intervention. The intervention will include 2 workshops, 5 support groups sessions and 2 individual counseling sessions. They will be interviewed and examined again after completing the intervention, to establish a post-intervention baseline.
Study NCT04365413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MSOT Device
Description: The MSOT Device will be used to take images of the tumor and/or lymph nodes of patients with solid tumors before and after surgery to measure the margins of the tumor and/or positive lymph node.
Study NCT04365413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temperature Measurement
Description: The temperature of the skin will be measured prior to and after MSOT imaging.
Study NCT00714233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 425mg. capsules, 2 capsules BID x 24 weeks
Study NCT00714233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Contraceptive Pills (Yasmin)
Description: Yasmin oral contraceptive tabs; 1 tab daily x 24 weeks
Study NCT00714233 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Modification
Description: weekly classes x 24 weeks for training in diet, exercise and behavior modification skills
Study NCT00714233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to the active metformin arm. 2 capsules BID x 24 weeks.
Study NCT01568190 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVANZ MITE
Description: Immunotherapy Dermatophagoides mix
Study NCT00690716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal CO2
Description: Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
Study NCT00690716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Placebo
Description: Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
Study NCT01190657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selbex
Description: 50mg/day, 3 times/day, for 14 days
Study NCT01190657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selbex
Description: 50mg/day, 3 times/day, for 56 days
Study NCT01666444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (PLD)
Study NCT03803917 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Injection with freshly collected autologous adipose tissue
Study NCT01241578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: Participants receive instructions for making healthy changes to their diet and physical activity habits.
Study NCT01666444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated liposomal doxorubicin (PLD)
Study NCT01666444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX-2337
Description: TLR8 Agonist
Study NCT01666444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT01761955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Dairy
Description: Consuming 4 or more servings of dairy products per day for a period of 6 months
Study NCT01861340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Dexamethasone, and MEDI-551
Description: Patients will receive Lenalidomide and dexamethasone as per standard of care. Patients with a clinical response after 2 cycles will get 2 cycles of MEDI-551.
Study NCT03860441 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computerized cognitive training
Description: Intervention used CogniFit platform with Personalized brain training sub-option
Study NCT00914199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Description: Implantation of coronary stent in bifurcation lesion.
Study NCT02786979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost
Description: Oral
Study NCT02786979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Oral
Study NCT03860441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Description: Intervention used CogniFit platform with Personalized brain training sub-option
Study NCT00214682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folate (400mcg) and Vitamin B12 (100 mcg)
Description: The vitamin intervention was a daily oral dose of one tablet consisting of folic acid 400 mcg + vitamin B12 100 mcg. The folic acid dose of 400 mcg / day was selected as it has been shown to be the dose associated with 90% of the maximal decrease in plasma homocysteine concentration for older individuals. Participants received 1 bottle x 200 tablets in six-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months).
Study NCT00797459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane and Restylane-L
Description: This is a split face design and each subject received both Restylane and Restylane-L. Treatments were double blind, randomized, and successive.
Study NCT04107857 — intervention group
Intervention type: BEHAVIORAL
Intervention: ELEVATE enhancement to electronic health record (EHR) to improve cessation counseling offer
Description: * Brief advise to quit smoking~* Referral to Missouri/Illinois Quitlines, Smokefree.TXT, or smokefree.gov
Study NCT04107857 — intervention group
Intervention type: BEHAVIORAL
Intervention: ELEVATE enhancement to electronic health record (EHR) to improve smoking cessation medication offer
Description: -Nicotine replacement therapy, varenicline, bupropion, or combination therapy (not provided by study)
Study NCT04107857 — intervention group
Intervention type: BEHAVIORAL
Intervention: Data Driven Feedback reports
Description: -Feedback reports will be based on data
Study NCT03282201 — intervention group
Intervention type: OTHER
Intervention: Transfusion
Description: Transfusion of red blood cells, fresh frozen plasma, platelets
Study NCT01166659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyPass Micro-Stent
Description: The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye. The CyPass is implanted in the eye.
Study NCT04227249 — intervention group
Intervention type: PROCEDURE
Intervention: no lymph node dissection
Description: do not undergo lymph node dissection
Study NCT04638699 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: OptiScreen training
Description: Special psycho-oncological training for nursing staff to acquire basic knowledge about the experience of mental stress as well as diagnostics of psychosocial stress
Study NCT04255875 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo
Study NCT04255875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07209326
Description: Participants will receive SC or IV single ascending doses
Study NCT04255875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07209326
Description: SCD participants will receive a multiple dose of subcutaneous PF-07209326
Study NCT03029338 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR T cells
Description: CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB.
Study NCT02927769 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified Dose on Specified Days
Study NCT02927769 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Specified Dose on Specified Days
Study NCT02927769 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: Specified Dose on Specified Days
Study NCT03169361 — intervention group
Intervention type: DRUG
Intervention: Ixazomib
Description: Ixazomib capsules
Study NCT02402972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FUDR +oxaliplatin
Description: IPC: one dose of fluorodeoxyuridine (FUDR) 1000 mg and oxaliplatin 100 mg were administered as a bolus into the regional vein
Study NCT02402972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin+Leucovorin+5-FU
Description: Adjuvant chemotherapy (AC): All patients received mFOLFOX6 adjuvant chemotherapy: oxaliplatin+Leucovorin+5-FU
Study NCT02402972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin+Leucovorin+5-FU
Description: Adjuvant chemotherapy (AC): All patients received mFOLFOX6 adjuvant chemotherapy: oxaliplatin+Leucovorin+5-FU
Study NCT01537653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR231893 (REGN668)
Description: Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
Study NCT00214682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mediated physical activity promotion
Description: Individuals in the Physical Activity Promotion group received a manual designed to promote older individuals' physical activity participation to the level recommended to gain both physical and mental health benefits. The framework of the physical activity manual was informed by social cognitive theory and the transtheoretical model, and comprised five sections that reflect stages of behaviour change, including; precontemplation, contemplation, preparation, action, and maintenance. The manual contained evidence-based strategies and skills to assist people in increasing their physical activity levels. Participants received a pedometer at the commencement of the intervention as pedometry step / minute values are useful as an indicator of moderate to vigorous physical activity with total number of steps for one week recorded during the brief telephone calls at 1-5 weeks, and 4-, 8-, 13-, 18-, and 22- months.
Study NCT00214682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental health literacy
Description: Comprises 10 modules, with nine of these specifically written for older adults. Modules 1 to 5 comprised information on depression and the evidence-based treatment for older adults. The additional MHL modules were booklets addressing evidence-based strategies and treatments for depression. It was delivered in a way to foster support and ensure that participants worked through the material systematically. Modules 1 to 5 were delivered in consecutive weeks as previous research indicates that the maximum impact of MHL on depressive symptoms may occur within the first six weeks of the intervention. Telephone interviewers contacted participants once a week for 5 consecutive weeks to motivate and support participants. There were an additional 5 check-in telephone calls, and Modules 6 to 10 of the MHL material that were delivered via postal mail at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10).
Study NCT00214682 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A placebo tablet was the attention control intervention for the folic acid + vitamin B12 intervention group. Participants received 1 bottle x 200 tablets in 6-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months) during which participants counted their left-over tablets.
Study NCT00214682 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition information
Description: The attention control intervention for the physical activity intervention was printed nutrition literacy and included information concerning the recommended dietary guidelines for older Australians, as well as strategies and additional information to facilitate beneficial dietary behaviours. The same procedure was adhered to as the physical activity intervention to ensure adequate attention control. Participants in the nutrition promotion intervention received 5 brief telephone calls from an interviewer to facilitate adherence to the intervention, and to offer support and clarification of the materials. Participants received five further brief telephone calls as well as nutrition newsletters that were delivered via postal mail at 4-, 8-, 13-, 18-, and 22- months.
Study NCT00214682 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pain and arthritis management information
Description: Pain and Arthritis Information was used as the attention control intervention for the MHL intervention and comprised 10 modules. Modules 1 to 5 were contained in an Arthritis Australia consumer guide for arthritis management. Modules 6 to 10 were a series of information pamphlets on pain management, osteoporosis and falls prevention. The delivery of the Pain Information was identical to the MHL intervention with Modules 1 to 5 distributed via postal mail in five consecutive weeks (1-5 weeks), while the remaining intervention modules were delivered at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10). Participants also received 10 brief calls from a telephone interviewer that coincided with receiving the print intervention materials.
Study NCT01537653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
Study NCT03242928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Description: 50 mg and 100 mg tablets taken orally
Study NCT00438750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Independent Excercises
Description: Subjects provided with wrist splint and instructions for independent exercises to perform at home on their own. Subjects were advised to perform exercises as often as possible, but at least three to four times a day for a minimum of thirty minutes. There was no formal strengthening program.
Study NCT00438750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Subjects were prescribed formal occupational therapy with supervised exercises to regain digit, wrist, and forearm motion and to strengthen the hand. The content, frequency, and duration of the rehabilitation program were at the discretion of the treating hand therapist.
Study NCT03242928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets taken orally BID
Study NCT04541849 — intervention group
Intervention type: OTHER
Intervention: Critical Care
Description: Critical care in the intensive care units
Study NCT03409315 — intervention group
Intervention type: PROCEDURE
Intervention: Centralized Therapeutic Drug Monitoring
Description: Plasma samples will be drawn at peripheral centres en shipped to a central laboratory for analysis. Results and dosing advice will be returned by email to local physician.
Study NCT02394444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triadic parent-infant Relationship Therapy (TRT)
Description: 22 sessions, including home visits twice per month during the first four months, followed by monthly consultations in the neonatology ward, up to corrected age of 18 months.
Study NCT01099839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral
Study NCT01099839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miglitol
Description: oral
Study NCT02024711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EYEFILL® C.-US Viscoelastic
Description: EYEFILL ® C.-US is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
Study NCT02024711 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Healon® Viscoelastic (CONTROL)
Description: Healon® is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
Study NCT04280601 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: vitamin D
Description: Patients with insufficient and/or deficient vitamin D status (\<75 nmol/L) at study enrolment will be instructed to take a 12-month supply of vitamin D3 supplementation (to a maximum of 2,000 IU/day) vs. those with sufficient status will be observed for 12-months
Study NCT00003546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: given IV
Study NCT00003546 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 1.8 Gy to tumor bed
Study NCT03357276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mix vaccine
Description: Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
Study NCT03299517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiarrythmic Drugs
Description: Patient will be randomly randomized 1: 1 for the antiarrythmic drugs. If there is no reversal and there is no adverse event, a further dose of the same pre-administered medicinal product will be performed in another 30 minutes.
Study NCT03299517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs
Description: Patient will be randomly randomized 1: 1 for the the antiarrythmic drugs. If there is no reversal and there is no adverse event, a further dose of the same pre-administered medicinal product will be performed in another 30 minutes.
Study NCT01005394 — intervention group
Intervention type: DEVICE
Intervention: Navigated TMS examination
Description: diagnostic examination using a single pulse TMS paradigm to evaluate corticospinal motor tract integrity and its evolution after stroke
Study NCT03601416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplantation of mesenchymal stem cell
Description: Human umbilical cord-derived mesenchymal stem cell will be given to participants through intravenous infusion.~Dose A - 1 million cells per kg Dose B - 5 million cells per kg
Study NCT03601416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Transplantation of Mesenchymal Stem Cell
Description: Human umbilical cord-derived mesenchymal stem cell will be not given to participants through intravenous infusion.
Study NCT01324583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (XRP6258)
Description: Pharmaceutical form:solution~Route of administration: intravenous
Study NCT01324583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Description: Pharmaceutical form:tablet~Route of administration: oral
Study NCT00120445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: air
Description: 0.3 ml of filtered air
Study NCT00120445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: expansile gas
Description: 0.3 ml of perfluoropropane gas
Study NCT03623321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: • Pimavanserin 34 mg is provided as 2×17 mg tablets as single dose, once daily by mouth. Dose adjustments of pimavanserin down to 20 mg (provided as 2×10 mg tablets as a single dose, once daily by mouth) and up to 34 mg are permitted based on Investigator assessment of clinical response.
Study NCT04002440 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: AMIA with SHARESOURCE Connectivity Platform
Description: The investigators will conduct a randomized, cross-over study in peritoneal dialysis patients in which patients are randomized to either Home Choice Pro (which remains the most widely used Baxter cycler) versus treatment with the Baxter AMIA automated peritoneal dialysis system with SHARESOURCE connectivity.
Study NCT04002440 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: HomeChoice PRO
Description: Usual care
Study NCT03819179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Burt's Bees Serum
Description: This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol.
Study NCT03819179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Burt's Bees Serum with Biulin
Description: This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, PreBIULIN FOS (GOVA).